POPULARITY
2 episodes with MS2
3 episodes with MS2
2 episodes with MS2
4 episodes with MS2
6 episodes with MS2
3 episodes with MS2
2 episodes with MS2
3 episodes with MS2
2 episodes with MS2
Listen to ASCO's JCO Oncology Practice, Art of Oncology Practice article, "An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last” by Dr. David Johnson, who is a clinical oncologist at University of Texas Southwestern Medical School. The article is followed by an interview with Johnson and host Dr. Mikkael Sekeres. Through humor and irony, Johnson critiques how overspecialization and poor presentation practices have eroded what was once internal medicine's premier educational forum. Transcript Narrator: An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last, by David H. Johnson, MD, MACP, FASCO Over the past five decades, I have attended hundreds of medical conferences—some insightful and illuminating, others tedious and forgettable. Among these countless gatherings, Medical Grand Rounds (MGRs) has always held a special place. Originally conceived as a forum for discussing complex clinical cases, emerging research, and best practices in patient care, MGRs served as a unifying platform for clinicians across all specialties, along with medical students, residents, and other health care professionals. Expert speakers—whether esteemed faculty or distinguished guests—would discuss challenging cases, using them as a springboard to explore the latest advances in diagnosis and treatment. During my early years as a medical student, resident, and junior faculty member, Grand Rounds consistently attracted large, engaged audiences. However, as medicine became increasingly subspecialized, attendance began to wane. Lectures grew more technically intricate, often straying from broad clinical relevance. The patient-centered discussions that once brought together diverse medical professionals gradually gave way to hyperspecialized presentations. Subspecialists, once eager to share their insights with the wider medical community, increasingly withdrew to their own specialty-specific conferences, further fragmenting the exchange of knowledge across disciplines. As a former Chair of Internal Medicine and a veteran of numerous MGRs, I observed firsthand how these sessions shifted from dynamic educational exchanges to highly specialized, often impenetrable discussions. One of the most striking trends in recent years has been the decline in presentation quality at MGR—even among local and visiting world-renowned experts. While these speakers are often brilliant clinicians and investigators, they can also be remarkably poor lecturers, delivering some of the most uninspiring talks I have encountered. Their presentations are so consistently lackluster that one might suspect an underlying strategy at play—an unspoken method to ensure that they are never invited back. Having observed this pattern repeatedly, I am convinced that these speakers must be adhering to a set of unwritten rules to avoid future MGR presentations. To assist those unfamiliar with this apparent strategy, I have distilled the key principles that, when followed correctly, all but guarantee that a presenter will not be asked to give another MGR lecture—thus sparing them the burden of preparing one in the future. Drawing on my experience as an oncologist, I illustrate these principles using an oncology-based example although I suspect similar rules apply across other subspecialties. It will be up to my colleagues in cardiology, endocrinology, rheumatology, and beyond to identify and document their own versions—tasks for which I claim no expertise. What follows are the seven “Rules for Presenting a Bad Medical Oncology Medical Grand Rounds.” 1. Microscopic Mayhem: Always begin with an excruciatingly detailed breakdown of the tumor's histology and molecular markers, emphasizing how these have evolved over the years (eg, PAP v prostate-specific antigen)—except, of course, when they have not (eg, estrogen receptor, progesterone receptor, etc). These nuances, while of limited relevance to general internists or most subspecialists (aside from oncologists), are guaranteed to induce eye-glazing boredom and quiet despair among your audience. 2. TNM Torture: Next, cover every nuance of the newest staging system … this is always a real crowd pleaser. For illustrative purposes, show a TNM chart in the smallest possible font. It is particularly helpful if you provide a lengthy review of previous versions of the staging system and painstakingly cover each and every change in the system. Importantly, this activity will allow you to disavow the relevance of all previous literature studies to which you will subsequently refer during the course of your presentation … to wit—“these data are based on the OLD staging system and therefore may not pertain …” This phrase is pure gold—use it often if you can. NB: You will know you have “captured” your audience if you observe audience members “shifting in their seats” … it occurs almost every time … but if you have failed to “move” the audience … by all means, continue reading … there is more! 3. Mechanism of Action Meltdown: Discuss in detail every drug ever used to treat the cancer under discussion; this works best if you also give a detailed description of each drug's mechanism of action (MOA). General internists and subspecialists just LOVE hearing a detailed discussion of the drug's MOA … especially if it is not at all relevant to the objectives of your talk. At this point, if you observe a wave of slack-jawed faces slowly slumping toward their desktops, you will know you are on your way to successfully crushing your audience's collective spirit. Keep going—you are almost there. 4. Dosage Deadlock: One must discuss “dose response” … there is absolutely nothing like a dose response presentation to a group of internists to induce cries of anguish. A wonderful example of how one might weave this into a lecture to generalists or a mixed audience of subspecialists is to discuss details that ONLY an oncologist would care about—such as the need to dose escalate imatinib in GIST patients with exon 9 mutations as compared with those with exon 11 mutations. This is a definite winner! 5. Criteria Catatonia: Do not forget to discuss the newest computed tomography or positron emission tomography criteria for determining response … especially if you plan to discuss an obscure malignancy that even oncologists rarely encounter (eg, esthesioneuroblastoma). Should you plan to discuss a common disease you can ensure ennui only if you will spend extra time discussing RECIST criteria. Now if you do this well, some audience members may begin fashioning their breakfast burritos into projectiles—each one aimed squarely at YOU. Be brave … soldier on! 6. Kaplan-Meier Killer: Make sure to discuss the arcane details of multiple negative phase II and III trials pertaining to the cancer under discussion. It is best to show several inconsequential and hard-to-read Kaplan-Meier plots. To make sure that you do a bad job, divide this portion of your presentation into two sections … one focused on adjuvant treatment; the second part should consist of a long boring soliloquy on the management of metastatic disease. Provide detailed information of little interest even to the most ardent fan of the disease you are discussing. This alone will almost certainly ensure that you will never, ever be asked to give Medicine Grand Rounds again. 7. Lymph Node Lobotomy: For the coup de grâce, be sure to include an exhaustive discussion of the latest surgical techniques, down to the precise number of lymph nodes required for an “adequate dissection.” To be fair, such details can be invaluable in specialized settings like a tumor board, where they send subspecialists into rapturous delight. But in the context of MGR—where the audience spans multiple disciplines—it will almost certainly induce a stultifying torpor. If dullness were an art, this would be its masterpiece—capable of lulling even the most caffeinated minds into a stupor. If you have carefully followed the above set of rules, at this point, some members of the audience should be banging their heads against the nearest hard surface. If you then hear a loud THUD … and you're still standing … you will know you have succeeded in giving the world's worst Medical Grand Rounds! Final Thoughts I hope that these rules shed light on what makes for a truly dreadful oncology MGR presentation—which, by inverse reasoning, might just serve as a blueprint for an excellent one. At its best, an outstanding lecture defies expectations. One of the most memorable MGRs I have attended, for instance, was on prostaglandin function—not a subject typically associated with edge-of-your-seat suspense. Given by a biochemist and physician from another subspecialty, it could have easily devolved into a labyrinth of enzymatic pathways and chemical structures. Instead, the speaker took a different approach: rather than focusing on biochemical minutiae, he illustrated how prostaglandins influence nearly every major physiologic system—modulating inflammation, regulating cardiovascular function, protecting the gut, aiding reproduction, supporting renal function, and even influencing the nervous system—without a single slide depicting the prostaglandin structure. The result? A room full of clinicians—not biochemists—walked away with a far richer understanding of how prostaglandins affect their daily practice. What is even more remarkable is that the talk's clarity did not just inform—it sparked new collaborations that shaped years of NIH-funded research. Now that was an MGR masterpiece. At its core, effective scientific communication boils down to three deceptively simple principles: understanding your audience, focusing on relevance, and making complex information accessible.2 The best MGRs do not drown the audience in details, but rather illuminate why those details matter. A great lecture is not about showing how much you know, but about ensuring your audience leaves knowing something they didn't before. For those who prefer the structured wisdom of a written guide over the ramblings of a curmudgeon, an excellent review of these principles—complete with a handy checklist—is available.2 But fair warning: if you follow these principles, you may find yourself invited back to present another stellar MGRs. Perish the thought! Dr. Mikkael SekeresHello and welcome to JCO's Cancer Stories: The Art of Oncology, which features essays and personal reflections from authors exploring their experience in the oncology field. I'm your host, Mikkael Sekeres. I'm Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami. What a pleasure it is today to be joined by Dr. David Johnson, clinical oncologist at the University of Texas Southwestern Medical School. In this episode, we will be discussing his Art of Oncology Practice article, "An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last." Our guest's disclosures will be linked in the transcript. David, welcome to our podcast and thanks so much for joining us. Dr. David JohnsonGreat to be here, Mikkael. Thanks for inviting me. Dr. Mikkael SekeresI was wondering if we could start with just- give us a sense about you. Can you tell us about yourself? Where are you from? And walk us through your career. Dr. David JohnsonSure. I grew up in a small rural community in Northwest Georgia about 30 miles south of Chattanooga, Tennessee, in the Appalachian Mountains. I met my wife in kindergarten. Dr. Mikkael SekeresOh my. Dr. David JohnsonThere are laws in Georgia. We didn't get married till the third grade. But we dated in high school and got married after college. And so we've literally been with one another my entire life, our entire lives. Dr. Mikkael SekeresMy word. Dr. David JohnsonI went to medical school in Georgia. I did my training in multiple sites, including my oncology training at Vanderbilt, where I completed my training. I spent the next 30 years there, where I had a wonderful career. Got an opportunity to be a Division Chief and a Deputy Director of, and the founder of, a cancer center there. And in 2010, I was recruited to UT Southwestern as the Chairman of Medicine. Not a position I had particularly aspired to, but I was interested in taking on that challenge, and it proved to be quite a challenge for me. I had to relearn internal medicine, and really all the subspecialties of medicine really became quite challenging to me. So my career has spanned sort of the entire spectrum, I suppose, as a clinical investigator, as an administrator, and now as a near end-of-my-career guy who writes ridiculous articles about grand rounds. Dr. Mikkael SekeresNot ridiculous at all. It was terrific. What was that like, having to retool? And this is a theme you cover a little bit in your essay, also, from something that's super specialized. I mean, you have had this storied career with the focus on lung cancer, and then having to expand not only to all of hematology oncology, but all of medicine. Dr. David JohnsonIt was a challenge, but it was also incredibly fun. My first few days in the chair's office, I met with a number of individuals, but perhaps the most important individuals I met with were the incoming chief residents who were, and are, brilliant men and women. And we made a pact. I promised to teach them as much as I could about oncology if they would teach me as much as they could about internal medicine. And so I spent that first year literally trying to relearn medicine. And I had great teachers. Several of those chiefs are now on the faculty here or elsewhere. And that continued on for the next several years. Every group of chief residents imparted their wisdom to me, and I gave them what little bit I could provide back to them in the oncology world. It was a lot of fun. And I have to say, I don't necessarily recommend everybody go into administration. It's not necessarily the most fun thing in the world to do. But the opportunity to deal one-on-one closely with really brilliant men and women like the chief residents was probably the highlight of my time as Chair of Medicine. Dr. Mikkael SekeresThat sounds incredible. I can imagine, just reflecting over the two decades that I've been in hematology oncology and thinking about the changes in how we diagnose and care for people over that time period, I can only imagine what the changes had been in internal medicine since I was last immersed in that, which would be my residency. Dr. David JohnsonWell, I trained in the 70s in internal medicine, and what transpired in the 70s was kind of ‘monkey see, monkey do'. We didn't really have a lot of understanding of pathophysiology except at the most basic level. Things have changed enormously, as you well know, certainly in the field of oncology and hematology, but in all the other fields as well. And so I came in with what I thought was a pretty good foundation of knowledge, and I realized it was completely worthless, what I had learned as an intern and resident. And when I say I had to relearn medicine, I mean, I had to relearn medicine. It was like being an intern. Actually, it was like being a medical student all over again. Dr. Mikkael SekeresOh, wow. Dr. David JohnsonSo it's quite challenging. Dr. Mikkael SekeresWell, and it's just so interesting. You're so deliberate in your writing and thinking through something like grand rounds. It's not a surprise, David, that you were also deliberate in how you were going to approach relearning medicine. So I wonder if we could pivot to talking about grand rounds, because part of being a Chair of Medicine, of course, is having Department of Medicine grand rounds. And whether those are in a cancer center or a department of medicine, it's an honor to be invited to give a grand rounds talk. How do you think grand rounds have changed over the past few decades? Can you give an example of what grand rounds looked like in the 1990s compared to what they look like now? Dr. David JohnsonWell, I should all go back to the 70s and and talk about grand rounds in the 70s. And I referenced an article in my essay written by Dr. Ingelfinger, who many people remember Dr. Ingelfinger as the Ingelfinger Rule, which the New England Journal used to apply. You couldn't publish in the New England Journal if you had published or publicly presented your data prior to its presentation in the New England Journal. Anyway, Dr. Ingelfinger wrote an article which, as I say, I referenced in my essay, about the graying of grand rounds, when he talked about what grand rounds used to be like. It was a very almost sacred event where patients were presented, and then experts in the field would discuss the case and impart to the audience their wisdom and knowledge garnered over years of caring for patients with that particular problem, might- a disease like AML, or lung cancer, or adrenal insufficiency, and talk about it not just from a pathophysiologic standpoint, but from a clinician standpoint. How do these patients present? What do you do? How do you go about diagnosing and what can you do to take care of those kinds of patients? It was very patient-centric. And often times the patient, him or herself, was presented at the grand rounds. And then experts sitting in the front row would often query the speaker and put him or her under a lot of stress to answer very specific questions about the case or about the disease itself. Over time, that evolved, and some would say devolved, but evolved into more specialized and nuanced presentations, generally without a patient present, or maybe even not even referred to, but very specifically about the molecular biology of disease, which is marvelous and wonderful to talk about, but not necessarily in a grand round setting where you've got cardiologists sitting next to endocrinologists, seated next to nephrologists, seated next to primary care physicians and, you know, an MS1 and an MS2 and et cetera. So it was very evident to me that what I had witnessed in my early years in medicine had really become more and more subspecialized. As a result, grand rounds, which used to be packed and standing room only, became echo chambers. It was like a C-SPAN presentation, you know, where local representative got up and gave a talk and the chambers were completely empty. And so we had to go to do things like force people to attend grand rounds like a Soviet Union-style rally or something, you know. You have to pay them to go. But it was really that observation that got me to thinking about it. And by the way, I love oncology and I'm, I think there's so much exciting progress that's being made that I want the presentations to be exciting to everybody, not just to the oncologist or the hematologist, for example. And what I was witnessing was kind of a formula that, almost like a pancake formula, that everybody followed the same rules. You know, “This disease is the third most common cancer and it presents in this way and that way.” And it was very, very formulaic. It wasn't energizing and exciting as it had been when we were discussing individual patients. So, you know, it just is what it is. I mean, progress is progress and you can't stop it. And I'm not trying to make America great again, you know, by going back to the 70s, but I do think sometimes we overthink what medical grand rounds ought to be as compared to a presentation at ASH or ASCO where you're talking to subspecialists who understand the nuances and you don't have to explain the abbreviations, you know, that type of thing. Dr. Mikkael SekeresSo I wonder, you talk about the echo chamber of the grand rounds nowadays, right? It's not as well attended. It used to be a packed event, and it used to be almost a who's who of, of who's in the department. You'd see some very famous people who would attend every grand rounds and some up-and-comers, and it was a chance for the chief residents to shine as well. How do you think COVID and the use of Zoom has changed the personality and energy of grand rounds? Is it better because, frankly, more people attend—they just attend virtually. Last time I attended, I mean, I attend our Department of Medicine grand rounds weekly, and I'll often see 150, 200 people on the Zoom. Or is it worse because the interaction's limited? Dr. David JohnsonYeah, I don't want to be one of those old curmudgeons that says, you know, the way it used to be is always better. But there's no question that the convenience of Zoom or similar media, virtual events, is remarkable. I do like being able to sit in my office where I am right now and watch a conference across campus that I don't have to walk 30 minutes to get to. I like that, although I need the exercise. But at the same time, I think one of the most important aspects of coming together is lost with virtual meetings, and that's the casual conversation that takes place. I mentioned in my essay an example of the grand rounds that I attended given by someone in a different specialty who was both a physician and a PhD in biochemistry, and he was talking about prostaglandin metabolism. And talk about a yawner of a title; you almost have to prop your eyelids open with toothpicks. But it turned out to be one of the most fascinating, engaging conversations I've ever encountered. And moreover, it completely opened my eyes to an area of research that I had not been exposed to at all. And it became immediately obvious to me that it was relevant to the area of my interest, which was lung cancer. This individual happened to be just studying colon cancer. He's not an oncologist, but he was studying colon cancer. But it was really interesting what he was talking about. And he made it very relevant to every subspecialist and generalist in the audience because he talked about how prostaglandin has made a difference in various aspects of human physiology. The other grand rounds which always sticks in my mind was presented by a long standing program director at my former institution of Vanderbilt. He's passed away many years ago, but he gave a fascinating grand rounds where he presented the case of a homeless person. I can't remember the title of his grand rounds exactly, but I think it was “Care of the Homeless” or something like that. So again, not something that necessarily had people rushing to the audience. What he did is he presented this case as a mysterious case, you know, “what is it?” And he slowly built up the presentation of this individual who repeatedly came to the emergency department for various and sundry complaints. And to make a long story short, he presented a case that turned out to be lead poisoning. Everybody was on the edge of their seat trying to figure out what it was. And he was challenging members of the audience and senior members of the audience, including the Cair, and saying, “What do you think?” And it turned out that the patient became intoxicated not by eating paint chips or drinking lead infused liquids. He was burning car batteries to stay alive and inhaling lead fumes, which itself was fascinating, you know, so it was a fabulous grand rounds. And I mean, everybody learned something about the disease that they might otherwise have ignored, you know, if it'd been a title “Lead Poisoning”, I'm not sure a lot of people would have shown up. Dr. Mikkael Sekeres That story, David, reminds me of Tracy Kidder, who's a master of the nonfiction narrative, will choose a subject and kind of just go into great depth about it, and that subject could be a person. And he wrote a book called Rough Sleepers about Jim O'Connell - and Jim O'Connell was one of my attendings when I did my residency at Mass General - and about his life and what he learned about the homeless. And it's this same kind of engaging, “Wow, I never thought about that.” And it takes you in a different direction. And you know, in your essay, you make a really interesting comment. You reflect that subspecialists, once eager to share their insight with the wider medical community, increasingly withdraw to their own specialty specific conferences, further fragmenting the exchange of knowledge across disciplines. How do you think this affects their ability to gain new insights into their research when they hear from a broader audience and get questions that they usually don't face, as opposed to being sucked into the groupthink of other subspecialists who are similarly isolated? Dr. David Johnson That's one of the reasons I chose to illustrate that prostaglandin presentation, because again, that was not something that I specifically knew much about. And as I said, I went to the grand rounds more out of a sense of obligation than a sense of engagement. Moreover, our Chair at that institution forced us to go, so I was there, not by choice, but I'm so glad I was, because like you say, I got insight into an area that I had not really thought about and that cross pollination and fertilization is really a critical aspect. I think that you can gain at a broad conference like Medical Grand Rounds as opposed to a niche conference where you're talking about APL. You know, everybody's an APL expert, but they never thought about diabetes and how that might impact on their research. So it's not like there's an ‘aha' moment at every Grand Rounds, but I do think that those kinds of broad based audiences can sometimes bring a different perspective that even the speaker, him or herself had not thought of. Dr. Mikkael SekeresI think that's a great place to end and to thank David Johnson, who's a clinical oncologist at the University of Texas Southwestern Medical School and just penned the essay in JCO Art of Oncology Practice entitled "An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last." Until next time, thank you for listening to JCO's Cancer Stories: The Art of Oncology. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all of ASCO's shows at asco.org/podcasts. David, once again, I want to thank you for joining me today. Dr. David JohnsonThank you very much for having me. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Show notes: Like, share and subscribe so you never miss an episode and leave a rating or review. Guest Bio: Dr David Johnson is a clinical oncologist at the University of Texas Southwestern Medical School.
Asian Battery Metals PLC managing director Gan-Ochir Zunduisuren talked with Proactive about the company's upcoming drilling activities at its Gambit Project in Mongolia. Zunduisuren confirmed that AZ9 is fully funded for its latest regional exploration program, which includes key targets MS1, MS2, and Copper Ridge. The MS1 and MS2 drill targets have never been drilled before. According to Zunduisuren, these are “coincidental, magnetic gravity and IP anomalies,” which may suggest a concealed magmatic system. He explained that this complements the ongoing exploration strategy at Oval and could help build a pipeline of future copper and nickel mineralization. Zunduisuren highlighted that at the Copper Ridge prospect, a previous drill hole intersected more than 137 metres of copper and gold mineralisation. He noted that the area “has a good potential for hosting independent systems,” and that the company will be following up with more drilling. Additionally, the exploration program will be expanding into the CA Far East area. The phase three drilling program at Oval continues in parallel, with all results — including lab assessments — expected by the second half of June. Zunduisuren said the company will provide the market with updates once data from both Oval and regional targets is available.
"Learning POCUS, Part 2: Training for Anesthesiologists and Our Future Generations" by Calah Myhre, MS2, Vivian Ip, MBChB, MRCP, FRCA, and Hari Kalagara, MD. From ASRA Pain Medicine News, May 2024. See original article at www.asra.com/may24news for figures and references. This material is copyrighted. Support the Show.
Join Annabel and MS2 legends, Calvin, Tara and JP as they serve up all the hot tea from Melbourne Survivor 2. Did Calvin set a new level of ORCA and what set off his blow hole? How did Tara pull off such an elite game where by her own admission two pods ago, she should have 'won' the who needs a wake up call in life answer in the survey challenge? Also JP bitches about everyone who was voted off after him (probably). Also voting remains open for the ORCA medal and also other awards of lesser significance. Vote here and vote soon, or forever hold your complaints! https://www.surveymonkey.com/r/HF6PVJJ
Join CK and the 'people's champion'; the one and only CM Barca as we dissect his fallen angel game and he talks about the members of his cast. Also voting is open for the Melbourne Survivor 2 ORCA awards including the all important Bromilow Medal. Who will join Ethan, Kevin, Matt, Dom and Andrew as the true ORCA of MS2. Vote here: https://www.surveymonkey.com/r/HF6PVJJ
Join CK and Dani as they recap all the action that was Melbourne Survivor 2. Is JP the best first boot in Oz LRG history? Is Jake's win actually controversial? How should you edit Strat Chat? Is Tara as amazing as you remember? All of these questions and more will be worked through so join us for all the spicy takes! Also voting is open for the Melbourne Survivor 2 ORCA awards including the all important Bromilow Medal. Who will join Ethan, Kevin, Matt, Dom and Andrew as the true ORCA of MS2. Vote here: https://www.surveymonkey.com/r/HF6PVJJ
"Learning POCUS, Part 1: The Benefits of an Early Introduction" by Calah Myhre, MS2, and Vivian Ip, MBChB, MRCP, FRCA. From ASRA Pain Medicine News, November 2023. See original article at www.asra.com/november23news for figures and references. This material is copyrighted. Support the show
Most students take the USMLE Step 1 in the spring or early summer towards the end of MS2. If you're in your second year, now might be a good time to start planning your approach to this daunting and monumental exam. Here, we lay out 5 steps that can help you prepare for the USMLE Step 1 while maintaining a positive mindset and trying to enjoy the process!
Contributors: Andrew White MD - Outpatient Psychiatrist; Fellowship Trained in Addiction Psychiatry; Denver Health Travis Barlock MD - Emergency Medicine Physician; Swedish Medical Center Summary In this episode of Mental Health Monthly, Dr. Travis Barlock hosts Dr. Andrew White to discuss the elements of mania that may be encountered in the emergency department. The discussion includes a helpful mnemonic to assess mania, work-up and treatment in the ED, underlying causes of mania, mental health holds, inpatient treatment, and the role of sleep in mania. Educational Pearls Initial assessment of suspected mania can be done via DIGFAST: Distractibility - Individual that is unable to carry a linear, goal-directed conversation Impulsivity - Executive functioning is impaired and patients are unable to control their behaviors Grandiosity - Elevated mood and sense of self to delusions of grandeur Flight of ideas - Usually described as racing thoughts Agitation - Increase in psychomotor activity; start several projects of which they have little previous knowledge Sleep decrease - Typically, manic episodes start with insomnia and can devolve into multiday sleeplessness Talkativeness - More talkative than usual with pressured speech and a tangential thought process Interviewing patients requires an understanding of mood-based mania vs. psychosis-based mania An individual with mood-based mania will more likely be restless, whereas a patient with psychosis-based mania will be more relaxed from a psychomotor standpoint Treatment of manic patients in the ED includes the use of antipsychotics to manage acute symptomatology Management can be informed and directed by the patient's history i.e. known medications that have worked for the patient ED management of manic patients involves a work-up for a broad differential including agitated delirium, substance-induced mania, metabolic disorders, and autoimmune diseases. Some individuals experience manic episodes from marijuana and other illicit substances Antidepressants used in bipolar patients for suspected depression may induce mania Important to avoid using antidepressants as first-line therapy Mental health holds can be beneficial in patients with grave disabilities from mania Oftentimes, undertreatment of manic episodes leads to re-hospitalization Inpatient treatment: Environment is important - ensure that patients get solo rooms if possible to minimize stimulation Antipsychotics, including risperidone and olanzapine, with or without a benzodiazepine, are useful for short-term agitation Long-term treatment involves coupled pharmacological treatments with non-pharmacological treatments Sleep Fractured sleep is one of the earliest warning signs that someone has an imminent manic episode Poor sleep can be an inciting factor for mania, which then turns into a cycle that further propagates a patient's manic episode Summarized and edited by Jorge Chalit, OMSII | Studio production by Jeffrey Olson, MS2
In this episode of BackTable ENT, Dr. Tammara Watts, surgeon-scientist at Duke University, sits down with host Dr. Gopi Shah to discuss two exciting scholarship opportunities for medical students available through the American Head & Neck Society (AHNS). --- SHOW NOTES Fewer than 5% of practicing otolaryngologists identify as members of underrepresented minority groups (URM), and these scholarships directly address that disparity. Gopi and Tammara then transition to discussing the importance of diversity in otolaryngology more broadly. First, Tammara expounds on what is gained by having a workforce that includes individuals with diverse backgrounds and experiences. Through the Dr. Eddie Méndez Research Fellowship and the Myers' Family Summer Fellowship, AHNS provides unique opportunities for aspiring otolaryngologists who identify as URM to connect with future colleagues. The Research Fellowship provides $10,000 to a medical student interested in spending one year immersed in otolaryngology research. It is unique in that AHNS provides a list of mentors (with bio-sketches) that interested applicants can connect with to formulate a research plan before applying. The Myers' Family Summer Fellowship financially supports a rising MS2 or MS3 student to gain exposure in Head & Neck Surgery. Next, Tammara offers tips on cultivating successful mentor-mentee relationships, emphasizing that mentors enjoy supporting their future colleagues, and that it is easier to do so when the mentee takes initiative. Finally, Tammara shares her philosophy regarding DEI. Though otolaryngologic patients come from all walks of life, their surgeons can't always conceptualize how their experiences influence their care. By supporting URM students interested in ENT, she (along with her AHNS colleagues) are helping create a workforce that can better understand and heal. --- RESOURCES AHNS's Dr. Eddie Méndez Fellowship: https://www.ahns.info/dr-eddie-mendez-research-fellowship/ AHNS's Myers' Family Summer Fellowship in Otolaryngology: https://www.ahns.info/myers-summer-fellowship/ Dr. Tammara Watts MD, PhD's Duke University Profile: https://headnecksurgery.duke.edu/profile/tammara-lynn-watts
¡Ni en vacaciones descansamos! :___DEsta semana os traemos lo siguiente:* MIERDAS VARIAS* Lucas se ‘compra' un Tesla y se instala paneles fotovoltaicos:* Proceso de compra* ¿Coste de hacer 100 km?* Extras y accesorios…* CarlinKit para CarPlay/Android Auto inalámbricos.* NOTICIAS RÁPIDAS* Google lanza Nearby Share para Windows.* Microsoft lanza PC Manager para ayudarnos a mantener a punto el PC.* Google lanza su Calendly: Calendario de citas, dentro de Google Calendar.* VIDEOGAMERS A LOS 40* Vuelven los 100 EUR de descuento en la Playstation 5 estándar. ¿Próximo anuncio de un modelo Pro/Slim?* Sony anuncia la PlayStation 5 Handheld y unos auriculares de botón.* La mala experiencia de Fer con la suscripción Premium de PlayStation.* RECOMENDACIONES* Juega desde tu teléfono a Slide to unlock.* Renueva online tu certificado digital FNMT.* Google lanza Google Collections.* Convertir videos a mp3 rápido y gratis con SaveMp3.* Accede a Lemmy desde tu teléfono con Bean (iOS) y Connect (Android).* Base MagSafe elago MS2.* La serie de Movistar+ Poquitª fe.MÉTODOS DE CONTACTORecordad que podéis contactar con nosotros:* En Mastodon: @doalvares, @heyazorin y @calvocast.* Blog: www.calvocast.com* En Instagram (donde colgamos las imágenes de lo que hablamos durante los podcasts): @calvocastpod* Por correo: calvocast@gmail.com* Déjanos una reseña en Apple Podcasts. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.calvocast.com
Food Safety Talk 4: Ode To A Pittsburgh (Michael Batz, Guest) — Food Safety Talkeero - Finally, wifi that worksShadow banning - Wikipediawhat3words /// The simplest way to talk about locationBianco Electric Company | Milltown NJ | FacebookModel devastated as she spots boyfriend cheating after going through food app - Daily StarWait Wait…Don't Tell Me! : NPRSpice Containers Pose Contamination Risk During Food Preparation | Rutgers UniversityCross-Contamination to Surfaces in Consumer Kitchens with MS2 as a Tracer Organism in Ground Turkey Patties | Journal of Food ProtectionNikki Shariat - University of Georgia College of Veterinary MedicineFood Safety Talk 90: What if it's a service dragon? — Food Safety TalkSalmonella Outbreaks Linked to Pet Bearded Dragons | CDCIs that a bearded dragon in your pocket or are you just happy to see me: walnut/Salmonella edition | barfblog
Samuel Owusu-Mireku an MS2 speaks to his adjustment during his first year. He is absolutely amazing and we get to hear how he overcame early struggles and how life has changed in his second year.
This episode highlights Dr. Mohagheghian Hossein, "Dr. Mo", who is a practicing emergency medicine physician in Missouri. Dr. Mo speaks about his path to medicine, what it is like being an emergency medicine physician with tattoos, balancing medicine with other passions in life, burnout, physician mental health, and more. This episode is hosted by Tyler Mouw, MS2.References:Mortensen, Karoline, et al. “Are Tattoos Associated with Negative Health‐Related Outcomes and Risky Behaviors?” International Journal of Dermatology, vol. 58, no. 7, 2019, pp. 816–824., https://doi.org/10.1111/ijd.14372.
Episode 121: Genital Herpes. Wendy and Grace discuss the signs, symptoms, diagnosis, and management of genital herpes. Written by Jaspreet Johal, MS4, Ross University School of Medicine. Edits by Grace Yi, MS2, University of California Los Angeles; and Wendy Collins, MS3, Ross University School of Medicine. Comments by Hector Arreaza, MD. December 1, 2022.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Definition & EpidemiologyGenital herpes is a common sexually transmitted infection caused by a virus called herpes simplex virus (HSV for short). There are two types of HSV. HSV type 1 commonly causes orolabial herpes (known as cold sores), and HSV type 2 typically causes genital herpes, which can present as painful blisters or ulcers in the genital regions. In recent years, an increasing number of genital herpes cases have been associated with HSV-1, especially in women. HSV infections are widespread among the global population and spread person to person through oral-to-oral contact or vaginal, anal, and oral sexual contact. Transmission can occur during periods of subclinical viral shedding, as in even when individuals are asymptomatic. In 2020, the seroprevalence of HSV-2 in the United States was approximately 13 percent among patients aged 15 to 49, with more women affected than men. Fifty to 80 percent of American adults have oral herpes (HSV-1), which causes cold sores or fever blisters in or around the mouth. HSV is a lifelong infection characterized by periodic reactivations that can be triggered by fatigue, stress, or illness, among other factors. Antiviral therapy can shorten symptom duration in primary infection and can also treat and prevent recurrences. Types of InfectionGenital HSV infection can be classified into three types: primary, nonprimary, and recurrent. Primary – Primary infection refers to an infection in a patient without preexisting antibodies to either HSV-1 or HSV-2.Nonprimary infection, a patient has a first occurrence of a genital HSV lesion but already has pre-existing HSV antibodies that are different from the HSV type related to the genital lesion.Recurrent – Recurrent infection refers to the reactivation of genital HSV (so the patient already has pre-existing antibodies in the serum)Clinical Features The incubation period for developing genital herpes after exposure ranges anywhere from 2 to 12 days.Most patients with primary HSV infection are asymptomatic or mildly symptomatic. However, in more severe cases, individuals can present with painful genital ulcers, dysuria, fever, tender local inguinal lymphadenopathy, and headache. HSV infection also presents with characteristic 2-4mm wide skin lesions that are vesicular or ulcerated. The vesicles are often clustered and can be fluid-filled with underlying erythema. Sometimes vesicles might have a depression in the center (called “umbilicated” vesicles.” It's important to note, though, that the clinical presentation can vary based on the type of infection (primary, nonprimary, or recurrent). As a general rule of thumb, the initial presentation of a non-primary genital infection tends to be milder (as in, fewer systemic symptoms and lesions) than that of a primary infection. Recurrent infections also tend to be less severe than primary or nonprimary infections. Also, around 50% of patients with symptomatic recurrent infections might experience prodromal symptoms in recurrent infections, like burning, pain, or pruritus, before lesions become visible.Symptoms in patients with primary infections typically resolve after an average of 19 days, whereas symptoms in nonprimary or recurrent infections resolve within 10 days. Also, there are no clear differences in a clinical presentation based on whether the virus is caused by HSV-1 or HSV-2. However, infections due to HSV-2 are associated with a higher recurrence rate than infections due to HSV-1. Extragenital complications Genital HSV infection can cause extragenital manifestations that typically occur during the primary episode of HSV infection but can reappear with subsequent episodes. Complications include aseptic meningitis, urinary bladder retention, proctitis, and lumbosacral radiculitis. Other areas that can be affected outside of the genital area are fingers, eyes, and other skin areas.Diagnosis.A clinical diagnosis of genital herpes is usually initiated by the finding of vesicular or ulcerated genital lesions. The diagnosis can be confirmed with lab testing like viral culture, polymerase chain reaction (PCR), direct fluorescence antibody, and type-specific serologic testing. The most appropriate test for a patient depends on their clinical presentation. We might opt for PCR-based testing and cell culture if a patient has active lesions. Viral culture has typically been the gold standard method to isolate HSV, but HSV PCR assays are becoming increasingly popular as they have the best overall sensitivity and specificity. Cell cultures are most accurate in the early stages of the disease and have greater diagnostic yield with primary as opposed to recurrent genital herpes. Another method, type-specific serologic testing, tells us if a patient has type-specific antibodies to HSV, which develop in the first few weeks after infection and persist indefinitely. We might opt for this method if a patient has a history of genital lesions without a diagnostic workup or if the patient has an atypical presentation, in which case we may get type-specific serologic testing in addition to PCR. Management. All individuals experiencing a first episode of genital HSV should be treated with antiviral therapy, ideally as soon as a lesion appears. Most cases of genital HSV can be treated with oral drug therapy for 7 to 10 days, and as of 2021, the CDC recommends 3 different options for treatment: acyclovir, famciclovir, and valacyclovir. These drugs have been shown to decrease the duration of lesion healing time, duration of pain, and duration of viral shedding. For example, if the disease is disseminated or ocular, we may use IV acyclovir in complicated infections. It is important to note that treating the initial episode does not eliminate the latent virus. Patients are still at risk for recurrence and may require additional antiviral therapy. For recurrent infections, treatment options include episodic therapy and chronic suppressive therapy. Episodic therapy – involves patients starting therapy at the very first sign of prodromal symptoms (tingling, paresthesia, pruritus). Patients with infrequent recurrences or mild symptoms might opt for episodic therapy. Wendy: Chronic suppressive therapy – involves daily antiviral therapy to decrease the risk of reactivation and recurrences. Suppressive therapy is helpful in patients with frequent recurrences or severe symptoms or at high risk for severe infections, such as those with HIV.ScreeningAccording to the US Preventive Services Task Force (USPSTF), routine screening for HSV-1 or HSV-2 is not recommended in asymptomatic adolescents and adults. The lack of specific treatment interventions for asymptomatic individuals, and the significant limitations of serologic testing, including low specificity and high false-positive rate, outweigh the potential benefits of screening. Prevention. Measures to prevent genital HSV infections include the use of barrier protection, patient education, and chronic suppressive therapy. Barrier protection – The use of condoms is one of the best ways to prevent the spread of genital HSV infection and other sexually transmitted diseases. It reduces the risk of transmission while patients are asymptomatic but are in the viral shedding stage. Patients with active lesions or prodromal symptoms should abstain from sexual activity completely while having an active episode. Patient Education – Counseling patients along with their sex partner(s) about safe sexual practices can decrease the incidence of HSV in our community and prevent the further spread of the disease. Chronic suppressive therapy – can reduce recurrences and viral transmission.Conclusion: Genital herpes is a sexually transmitted, worldwide infection that can be asymptomatic but often presents with painful vesicles that progress to ulcers in the genital area. Even though the course can be shortened, and the symptoms can be improved with medications, it is frequently recurrent. So, prevention is key to avoiding complications.________________________________Now we conclude episode number 121, “Genital herpes.” You listened to Grace and Wendy discuss the basics of genital herpes. They explained that episodic treatment of genital herpes with antivirals helps reduce the severity and duration of symptoms, while suppressive therapy prevents recurrences and transmission. Dr. Arreaza reminded us that screening asymptomatic adults and adolescents is not recommended by the USPSTF. HSV serology has a low sensitivity and specificity. PCR and viral culture are better diagnostic tools in most cases. And, as with all other STIs, promoting safe sex practices is key to the prevention of genital herpes.We thank Hector Arreaza, Grace Yi, Wendy Collins, and Jaspreet Johal this week. Audio edition by Adrianne Silva.Even without trying, you go to bed a little wiser every night. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you. Send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________Links:Albrecht, Mary A. Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection, Up to Date, last updated: Dec 22, 2020. https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-infection.Albrecht, Mary A. Treatment of genital herpes simplex infection, Up to Date, last updated: Jun 28, 2021. https://www.uptodate.com/contents/treatment-of-genital-herpes-simplex-virus-infectionJames C, Harfouche M, Welton NJ, Turner KM, Abu-Raddad LJ, Gottlieb SL, Looker KJ. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull World Health Organ. 2020 May 1;98(5):315-329. doi: 10.2471/BLT.19.237149. Epub 2020 Mar 25. PMID: 32514197; PMCID: PMC7265941. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265941/Royalty-free music used for this episode: “Keeping Watch,” New Age Landscapes. Downloaded on October 13, 2022, from https://www.videvo.net/royalty-free-music-albums/new-age-landscapes/.
Want to know what medical school is actually like? These four medical students are in different phases of their medical school programs and will provide you with their perspective based on their experience. On our panel we have...Emamoke Stephen Odafe is an MS1 at the Uniformed Services University of the Health and Sciences. Sarah Bradley, an MS2 at the Medical University of South Carolina. Luke Hendrix, an MS3 at UT Health San Antonio, MD program. And Yunus Tekin, a 4th year DO medical student at Burrell College of Osteopathic MedicineMentioned in this episode:Ad 2022 11 21 MSHQ BFCM
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.10.18.512791v1?rss=1 Authors: Truong, T., Johnston, S. M., Webber, K., Boekweg, H., Lundgren, C., Liang, Y., Nydegger, A., Xie, X., Payne, S. H., Kelly, R. T. Abstract: The sensitivity of single-cell proteomics (SCP) has increased dramatically in recent years due to advances in experimental design, sample preparation, separations and mass spectrometry instrumentation. Further increasing the sensitivity of SCP methods and instrumentation will enable the study of proteins within single cells that are expressed at copy numbers too small to be measured by current methods. Here we combine efficient nanoPOTS sample preparation and ultra-low-flow liquid chromatography with a newly developed data acquisition and analysis scheme termed wide window acquisition (WWA) to quantify greater than 3,000 proteins from single cells in fast label-free analyses. WWA is based on data-dependent acquisition (DDA) but employs larger precursor isolation windows to intentionally co-isolate and co-fragment additional precursors along with the selected precursor. The resulting chimeric MS2 spectra are then resolved using the CHIMERYS search engine within Proteome Discoverer 3.0. Compared to standard DDA workflows, WWA employing isolation windows of 8-12 Th increases peptide and proteome coverage by ~28% and ~39%, respectively. For a 40-min LC gradient operated at ~15 nL/min, we identified an average of 2,150 proteins per single-cell-sized aliquots of protein digest directly from MS2 spectra, which increased to an average of 3,524 proteins including proteins identified with MS1-level feature matching. Reducing the active gradient to 20 min resulted in a modest 10% decrease in proteome coverage. We also compared the performance of WWA with DIA. DIA underperformed WWA in terms of proteome coverage, especially with faster separations. Average proteome coverage for single HeLa and K562 cells was respectively 1,758 and 1,642 based on MS2 identifications with 1% false discovery rate and 3042 and 2891 with MS1 feature matching. As such, WWA combined with efficient sample preparation and rapid separations extends the depths of the proteome that can be studied at the single-cell level. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC
The IMG Podcast will be hosting a new series exclusive to our Podcast. Match a Resident ambassadors will be discussing mental health concerns that can arise during medical school and match seasons. Match a Resident wants to be at the frontlines at removing the stigma surrounding mental health. We're all in this together.On this episode we speak to Victor Adedara! Hear his mental health journey here."I am Victor O. Adedara from Brooklyn, New York, where I learned about myself. I attended the City University of New York/City Tech, where I obtained a BSc in Biomedical Informatics, an Associate degree in Chemical Technology, and a master's degree in Translational medicine from City College of New York. My medical inspiration journey started at the age of 16 when I firsthand experienced a lack of cultural competency. My experience propelled me to explore more in the medical field. I was determined to attend medical school. In doing so, I enrolled in a science major, which I realized was not a requirement. I conducted four years of benchwork research during my undergrad and represented my college in a research exchange program in Colombia. My experience in Colombia was a memorable one. I felt welcomed by the people. I was taught Spanish as the day went by. I was interested in being culturally aware and culturally humbled. All these attributes made me realize I would be a great physician. So, I went on to shadow a physician in 2016 and attended a minority in medicine program at Sidney Kimmel Medical College, where I learned a lot about ways to tackle social determinants of health. Currently, I am an MS2 at St Georges University School of Medicine. I chose to attend SGU because of its resources and how it shapes future physicians."
As the COVID-19 Pandemic has pushed more and more people to adopt virtual alternatives to previously in-person events, the sales of blue-light blocking glasses have boomed. These “magical” lenses claim to stop eye strain and computer use-related headaches in their tracks. Dr. Mark DeSantis, MD, an ophthalmologist with 40 years of experience and CUSM guest faculty, is here to explain the physics behind blue light, best eye practices for computer users, and if it's really worth it to splurge for blue-light blocking lenses. This episode is hosted by our wonderful medical student, Michael Lonsway, MS2.
In the winter of 2020, Shelby Houlihan, a middle distance Olympic runner, received a 4-year ban due to a doping accusation. She claimed that an unusual dinner was the culprit. Dr. Connelly breaks down the feasibility of Shelby's boar burrito defense using pharmacology. This episode is hosted by our wonderful medical student who also happens to be a competitive runner, Angela Chen, MS2.
Host - Hudson Lee, MS2, Weill Cornell Medical CollegeGuest - Aaron Glatt, MD, MACP, FIDSA, FSHEA, Chair, Dept. of Medicine, Chief, Infectious Diseases and Hospital Epidemiologist at Mount Sinai South Nassau
Host - Hudson Lee, MS2, Weill Cornell Medical CollegeGuest - Aaron Glatt, MD, MACP, FIDSA, FSHEA, Chair, Dept. of Medicine, Chief, Infectious Diseases and Hospital Epidemiologist at Mount Sinai South Nassau
Host - Hudson Lee, MS2, Weill Cornell Medical CollegeGuest - Aaron Glatt, MD, MACP, FIDSA, FSHEA, Chair, Dept. of Medicine, Chief, Infectious Diseases and Hospital Epidemiologist at Mount Sinai South Nassau
Host - Hudson Lee, MS2, Weill Cornell Medical CollegeGuest - Aaron Glatt, MD, MACP, FIDSA, FSHEA, Chair, Dept. of Medicine, Chief, Infectious Diseases and Hospital Epidemiologist at Mount Sinai South Nassau
Host - Hudson Lee, MS2, Weill Cornell Medical CollegeGuest - Aaron Glatt, MD, MACP, FIDSA, FSHEA, Chair, Dept. of Medicine, Chief, Infectious Diseases and Hospital Epidemiologist at Mount Sinai South Nassau
Host - Hudson Lee, MS2, Weill Cornell Medical CollegeGuest - Aaron Glatt, MD, MACP, FIDSA, FSHEA, Chair, Dept. of Medicine, Chief, Infectious Diseases and Hospital Epidemiologist at Mount Sinai South Nassau
All about Innovations, a Kerala-based innovation firm has come up with an of its kind ‘ion-based COVID solution' - ‘Wolf Airmask' to let you breathe fear-free. It is the only device in the world that can produce 100 percent negative ions efficiently to an area of 1000 sq ft and 10,000 cu ft. However, the range of the device can be enhanced to suit even larger areas. It produces no positive ions or ozone that is harmful to nature. The Wolf Airmask is also the only device tested against the SARS-CoV-2 virus. The device has been tested and approved by Rajiv Gandhi Centre for Biotechnology (RGCB). The organization has certified the device to be capable of neutralizing the COVID viral load in the air and surfaces by 99.9 percent. Wolf Airmask has been successfully tested against other viruses and MS2 bacteria as well. The Wolf Airmask can discharge up to 100 trillion negative ions per cm3/second which bind with the surface protein/spike protein of coronavirus or any other harmful virus and microbes present in the air and neutralize it. When the device is placed in an area, it ensures that the nearby premises are purified within no time. In my conversation with Sujesh Sajjan - Founder, Chairman of All about Innovations, we could understand the origins of Wolf Air Mask, their strides in handling the COVID first wave, and how they designed Wolf Air Mask at the roundabout of their continuous endeavors. Wolf Air Mask is currently a non-regulatory medical device that is designed for easiness and comfort as it is plug & play and requires no maintenance for 70,000 hours (approx eight years). The cost is just Rs 29,500 to secure an area of 1000 sq ft and 10,000 cu ft. The device can be easily installed in corporate offices, commercial spaces, residential places, hotels & restaurants, and spas & saloons among many other spaces, where there are large human gatherings. https://www.linkedin.com/company/allabout-innovations/ - Linkedin Page https://www.linkedin.com/in/sujesh-sugunan-3a42489/ - Profile of Sujesh Sugunan
Hi/As salam u alikum (peace and blessings) people ! On this episode of the "LET'S WALK" we have Andy Nguyen a.k.a ND MD, a Medical student (MS2), filmmaker and a creative at heart. We talk about his journey to med school, mental health, pursuing hobbies and creative pursuits, balancing life and much more. Join us as he shares his journey ! Listen to the podcast on your favorite platform Anchor Website https://anchor.fm/atta-rahman Apple Podcast https://podcasts.apple.com/us/podcast/lets-walk/id1523517217?uo=4 Spotify: https://open.spotify.com/show/254RR1nas9ffOa1Uqdo5fw Google Podcasts: https://www.google.com/podcasts?feed=aHR0cHM6Ly9hbmNob3IuZm0vcy8yYjk5ZDdhNC9wb2RjYXN0L3Jzcw== For inquiries e-mail reach.attarahman@gmail.com Say Hi Andy Website- https://www.ndmdproductions.com/ Instagram- https://www.instagram.com/andy_nguyen9/ YouTube- https://www.youtube.com/channel/UCWQSmcu8ShIF9s6YdsjxXFw Buy some Coffee https://nguyencoffeesupply.com/?ref=andynguyen9 Atta Rahman Facebook- https://www.facebook.com/attaarrahman/?ref=bookmarks Instagram - @attaarrahman https://www.instagram.com/attaarahman/ Twitter- https://twitter.com/attaarahman LinkedIn- https://www.linkedin.com/in/atta-rahman-2755b6195/ YouTube- https://www.youtube.com/channel/UCDagx3nn2aHKL85i5UZj2K Timestamps: 00:00:32 - Calling to medicine and the med school system in US 00:05:11 - Performing well in school and balancing life 00:12:11 - Mental Health and pursuing creative pursuits 00:30:25 - BS/MD program at Medical College of Georgia, Augusta University 00:43:18 - How med school changed him as a person 00:54:31 - PRESPECTIVE Note: The views expressed by our guest do not necessarily reflect the views of LET'S WALK or it's host(s) Thank you for listening/watching ! About: Salam/Hi! I am Atta, a pharmacy student, business development manager, nutrition consultant a.k.a "Ace" of all trades. I love talking to people who are creating a positive impact and lead by action. I love learning new things. Sometimes I just go off a tangent, anyways I post it. #LETSWALK
This episode features Black women medical students across the nation and the globe in order to discuss how far medical education has come since the start of the Black Lives Matter movements. Many institutions and corporations committed to fighting racism and white supremacy last summer, but where are we now? Hosted by Farrah-Amoy Fullerton, 4th-year medical student at UABSOM. Watch LiveStream of this episode at LaidBlack Podcast on Youtube (https://www.youtube.com/watch?v=wWzWJLozatk) Meet the Panelists: Kyshari McCullough, OMS4 at Ohio University in Columbus, OH Alana Parker, MS3 at CUNY School of Medicine Sallyanna Bazelais, MS3 at TouroCOM Courtney Chineme, OMS-3 at RowanSOM Erycka Webb, MS4 at Saba University School of Medicine Kika Otiono, MS2 at McMaster University in Canada
In the 5th episode of the “The Best and Worst” mini series, Alex Harrelson, MS2 sits down with psychiatry and palliative care specialist, Dr. John Shuster, to discuss his career and what life is truly like as a psychiatry and palliative care physician. Tune in to also hear Dr. Shuster discuss the history of the[...]
COVID-19 and the 2020 pandemic has drastically changed the delivery of medical education during the pre-clinical years. Class representatives to the curriculum teams have a unique perspective from the student and faculty perspective on what this transition from the classroom has been like. In Part 2 of this series, we hear from two current MS2's and curriculum representatives at UCF College of Medicine, Brandon Tapasak and Rachna Sannegowda, on what that transition has been like.
COVID-19 and the 2020 pandemic has drastically changed the delivery of medical education during the pre-clinical years. Class representatives to the curriculum teams have a unique perspective from the student and faculty perspective on what this transition from the classroom has been like. In Part 1 of this series, we hear from two current MS2's and curriculum representatives at Temple University School of Medicine, Vineet Naran and Michael Eckert, on what that transition has been like.
Welcome back to our Health Systems Science series! This episode Healthcare Delivery, Economics, and Policy. Today’s guests are Dr. Paul Weber, Associate Dean--Continuing Medical Education at Rutgers-Robert Wood Johnson & New Jersey Medical Schools and Kate Kim, MS2. The “Healthcare Policy and Emergency Preparedness” electives provide an innovative approach to the Health Systems Science curriculum at Rutgers Robert Wood Johnson Medical School. The curriculum, adaptable to both a virtual format and the inclusion of dynamic current events, includes the fundamentals of healthcare policy, health insurance and reimbursement, advocacy and the legislative process, the role of social media in healthcare, and the roles of various healthcare stakeholders. Sections from this episode include: Details and the origin of the “Healthcare Policy and Emergency Preparedness” elective Question breakdowns covering HiPPA and what is and is not a protected entity Medical billing practices included fee for service compared to value based healthcare. With support from Elsevier, and produced in collaboration with the American Medical Association, the HSS series seeks to broaden students’ understanding of the nature of medicine, medical education, and what separates them from other human endeavors. Medicine is not a “pure science,” a kind of “applied biology.” Rather, it is fundamentally an art that uses science. As a discipline, Health Systems Science considers those ideas and concepts which are integral to medicine as a profession but don’t fall under the domain of the clinical or basic sciences. The National Board of Medical Examiners includes HSS topics in its USMLE Content Outline and even offers a dedicated Health Systems Science subject examination. Each episode of this series will include on-the-go learning with practice exam questions explained by expert guests. Sponsor This series is sponsored by Panacea Financial: Banking Built for Doctors, by Doctors. ITB and Panacea share a common goal which is to make med school better. Panacea Financial is designed to handle the unique situation of medical students. We hope you will check them out to see how they can make your life easier. Learn more about the series and view the content outline on the ITB website. https://insidetheboards.com/Health-Systems-Science/. You can also listen to episodes in the ITB app organized into an HSS Playlist.
Dr. Barinder (Ricky) Hansra joins the show to share helpful tips for virtual interviewing. With interviews being conducted on Zoom and similar platforms this year, applicants must prepare and perform in new ways. The wisdom Dr. Hansra has gained from his experience matching into residency and two fellowships is sure to help!
In this episode, Jacob Schreiber interviews Devin Schweppe about the analysis of mass spectrometry data in the field of proteomics. They begin by delving into the different types of mass spectrometry methods, including MS1, MS2, and, MS3, and the reasons for using each. They then discuss a recent paper from Devin, Full-Featured, Real-Time Database Searching Platform Enables Fast and Accurate Multiplexed Quantitative Proteomics that involved building a real-time system for quantifying proteomic samples from MS3, and the types of analyses that this system allows one to do. Links: Full-Featured, Real-Time Database Searching Platform Enables Fast and Accurate Multiplexed Quantitative Proteomics (Devin K. Schweppe, Jimmy K. Eng, Qing Yu, Derek Bailey, Ramin Rad, Jose Navarrete-Perea, Edward L. Huttlin, Brian K. Erickson, Joao A. Paulo, and Steven P. Gygi) Benchmarking the Orbitrap Tribrid Eclipse for Next Generation Multiplexed Proteomics (Qing Yu, Joao A Paulo, Jose Naverrete-Perea, Graeme C McAlister, Jesse D Canterbury, Derek J Bailey, Aaron M Robitaille, Romain Huguet, Vlad Zabrouskov, Steven P Gygi, Devin K Schweppe) Improved Monoisotopic Mass Estimation for Deeper Proteome Coverage (Ramin Rad, Jiaming Li, Julian Mintseris, Jeremy O’Connell, Steven P. Gygi, and Devin K. Schweppe) Schweppe Lab Website (Hiring!)
Hi everybody, today we're interviewing Vishal Venkatraman, who is an MS2 at Duke University School of Medicine! Today Vishal will go into the interview day at Duke, student life, and other unique aspects about the school. Enjoy! Music: Tropical Traveller by Del. https://soundcloud.com/del-sound Disclaimer: The insights discussed in this podcast only hold true to this one student and do not represent the entire medical school, its constituents, or anyone else affiliated with the school. This student is not an official representative of the school and the opinions shared should not be seen as facts that the school has confirmed.
Hi everybody, today we're interviewing Eren Sipahi, who is an MS2 at Michigan State University College of Human Medicine! Today Eren will go into the interview day at MSU, student life, and other unique aspects about the school. Enjoy! Music: Tropical Traveller by Del. https://soundcloud.com/del-sound Disclaimer: The insights discussed in this podcast only hold true to this one student and do not represent the entire medical school, its constituents, or anyone else affiliated with the school. This student is not an official representative of the school and the opinions shared should not be seen as facts that the school has confirmed.
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.10.15.340638v1?rss=1 Authors: Guan, Y., Hu, J., Cao, W., Cui, W., Yang, F., Krisp, C., Lin, L., Zhang, M., Voss, H., Schuster, R., Yan, G., Fuh, M. M., Thaysen-Andersen, M., H. Packer, N., Shen, H., Yang, P., Schlüter, H. Abstract: Global in-depth analysis of N-glycosylation, as the most complex post-translational modification of proteins, is requiring methods being as sensitive, selective and reliable as possible. Here, an enhanced strategy for N-glycomics is presented comprising optimized sample preparation yielding enhanced glycoprotein recovery and permethylation efficiency, isotopic labelling for data quality control and relative quantification, integration of new N-glycan libraries (human and mouse), newly developed R-scripts matching experimental MS1 data to theoretical N-glycan compositions and bundled sequencing algorithms for MS2-based structural identification to ultimately enhance the coverage and accuracy of N-glycans. With this strategy the numbers of identified N-glycans are more than doubled compared with previous studies, exemplified by etanercept (more than 3-fold) and chicken ovalbumin (more than 2-fold) at nanogram level. The power of this strategy and applicability to biological samples is further demonstrated by comparative N-glycomics of human acute promyelocytic leukemia cells before and after treatment with all-trans retinoic acid, showing that N-glycan biosynthesis is slowed down and 57 species are significantly altered in response to the treatment. This improved analytical platform enables deep and accurate N-glycomics for glycobiological research and biomarker discovery. Copy rights belong to original authors. Visit the link for more info
September is Women in Medicine Month (#WIMMonth) and this got us thinking. In this two-part special series that hits extremely close to home, we hear from four MS2's who are leaders within the American Medical Women's Association (AMWA). These conversations shed light on a wide range of topics - from family life to advocacy to how everyone has a role within the women in medicine movement. Tune in and join us! In part two, we talk to Susie Soto and Jil Shah, board members of the UCF College of Medicine's AMWA chapter. Listen in for their truly motivating thoughts on how to find your own strengths, know your worth, and use your unique qualities to ultimately serve patients and the community!
September is Women in Medicine Month (#WIMMonth) and this got us thinking. In this two-part special series that hits extremely close to home, we hear from four MS2's who are leaders within the American Medical Women's Association (AMWA). These conversations shed light on a wide range of topics - from family life to advocacy to how everyone has a role within the women in medicine movement. Tune in and join us! In part one, we talk to Hannah Schwartz and Khyati Somayaji, co-presidents of Temple University's AMWA chapter. Listen in for their extremely thoughtful perspectives on the work-life balance and how we, as medical students, can continue to live our lives outside of school!
Hi everybody, today we're interviewing Ronus Hojjati, who is an MS2 at Northwestern University Feinberg School of Medicine! Today Ronus will go into the interview day at Northwestern, student life, and other unique aspects about the school. Enjoy! Music: Tropical Traveller by Del. https://soundcloud.com/del-sound Disclaimer: The insights discussed in this podcast only hold true to this one student and do not represent the entire medical school, its constituents, or anyone else affiliated with the school. This student is not an official representative of the school and the opinions shared should not be seen as facts that the school has confirmed.
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.09.03.281543v1?rss=1 Authors: van Olst, L., Rodriguez-Mogeda, C., Picon-Munoz, C., Kiljan, S., James, R. E., Kamermans, A., van der Pol, S. M. A., Knoop, L., Drost, E., Franssen, M., Schenk, G., Geurts, J. J. G., Amor, S., Mazarakis, N. D., van Horssen, J., de Vries, H. E., Reynolds, R., Witte, M. E. Abstract: Meningeal inflammation strongly associates with demyelination and neuronal loss in the underlying cortex of progressive MS patients, contributing to clinical disability. However, the pathological mechanisms of meningeal inflammation-induced cortical pathology are still largely elusive. Using extensive analysis of human post-mortem tissue, we identified two distinct microglial phenotypes, termed MS1 and MS2, in the cortex of progressive MS patients. These phenotypes differed in morphology and protein expression, but both associated with inflammation of the overlying meninges. We could replicate the MS-specific microglial phenotypes in a novel in vivo rat model for progressive MS-like meningeal inflammation, with microglia present at 1 month post-induction resembling MS1 microglia whereas those at 2 months acquired an MS2-like phenotype. Interestingly, MS1 microglia were involved in presynaptic displacement and phagocytosis and associated with a relative sparing of neurons in the MS and animal cortex. In contrast, the presence of MS2 microglia coincided with substantial neuronal loss. Taken together, we uncovered that in response to meningeal inflammation, microglia acquire two distinct phenotypes that differentially associate with neurodegeneration in the progressive MS cortex. Our data suggests that these phenotypes occur sequentially and that microglia may lose their protective properties over time, contributing to neuronal loss. Copy rights belong to original authors. Visit the link for more info
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2768888 Serial Bone Density Measurement and Incident Fracture Risk Discrimination in Postmenopausal Women Carolyn J. Crandall, MD, MS1; Joseph Larson, MS2; Nicole C. Wright, PhD3; et al OBJECTIVE To assess whether a second BMD measurement approximately 3 years after the initial assessment is associated with improved ability to estimate fracture risk beyond the baseline BMD measurement alone. In this prospective observational study 7419 women from The Women’s Health Initiative with a mean (SD) follow-up of 12.1 (3.4) years Incident major osteoporotic fracture (ie, hip, clinical spine, forearm, or shoulder fracture), hip fracture, baseline BMD, and absolute change in BMD were assessed a second bone mineral density (BMD) assessment approximately 3 years after the initial measurement was not associated with improved risk discrimination, beyond the initial BMD assessment, between women who did and did not experience hip fracture or major osteoporotic fracture. . I hate this because it add nothing!! The uspstf came out in 2018 and said in their guidelines titled Screening for Osteoporosis to Prevent FracturesUS Preventive Services Task Force Recommendation Statement THEY SAID AND I QOUTE!! However, limited evidence from 2 good-quality studies found no benefit in predicting fractures from repeating bone measurement testing 4 to 8 years after initial screening. Do the trial we all want to see with follow up for 10 or 12 or 15 yrs or don’t do the trial you are just wasting time and money on what we already know! Next article Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates Nejm 196,129 women 50 years of age or older who were receiving bisphosphonates and who were enrolled in the Kaiser Permanente Southern California health care system; women were followed from January 1, 2007, to November 30, 2017 primary outcome was atypical femur fracture- usually defined as fractures in the subtrochanteric region and along the femoral diaphysis 277 atypical femur fractures occurred hazard ratio went from 8.86 at 3-5 yrs (95% confidence interval [CI], 2.79 to 28.20) up to 43.51 (95% CI, 13.70 to 138.15) for 8 years or more. (likely why guidelines say stop at 5 yrs or at least take a drug holiday) when you look at the data it appears to be exponential that longer you on a biphosphonate the more likely you are to have an atypical fracture. But the thing I like most about this study is a huge data set that tells us on average since there was 196,129 women, and 277 atypical femur fractures occurred then baseline normal is (1.74 fractures per 10,000 patient-years) They also used a computer model to try and figure out how many fractures were prevented and depending on your race at 5 years there were anywhere from 500-800 fracture prevented We don’t have information like what was the baseline dexa, how were these people started on bisphosphonate but we can say they do prevent fractures and if you are concerned about atypical fractures the data would say it happens about 1 in every 5000 women. https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21628 “All participants (GDG members, ACS staff, expert advisors) were required to disclose financial and nonfinancial (personal, intellectual, practice‐related) relationships and activities related to cervical cancer and screening that might be perceived as posing a conflict of interest.” The American Cancer Society (ACS) now says average-risk individuals should begin cervical cancer screening at age 25 — rather than at age 21, as recommended in 2012. The group's guideline update appears in CA: A Cancer Journal for Clinicians. The other major change from 2012: The preferred screening approach is primary human papillomavirus (HPV) testing (i.e., stand-alone testing for high-risk HPV types) every 5 years through age 65. If FDA-approved primary HPV testing is not available, then HPV-cytology cotesting every 5 years or cytology alone every 3 years is acceptable. Of note, there are currently two approved primary HPV tests, and access to them may be limited. The ACS says that cotesting or cytology alone "should be phased out once full access to primary HPV testing for cervical cancer screening is available without barriers." The guidance applies to all average-risk, asymptomatic people with a cervix, including transgender men who still have a cervix. Such individuals should be screened regardless of their HPV vaccination status or sexual history. Randomized, double-blind, placebo-controlled trial of intraarticular trans-capsaicin for pain associated with osteoarthritis of the knee. Stevens RM, Ervin J, Nezzer J, et al. Arthritis Rheumatol. 2019;71(9):1524-1533. doi: 10.1002/art.40894. double-blind, randomized, placebo-controlled trial of adult patients (45 to 80 years of age) with X-rays showing chronic OA, pain for at least two months, and mean pain score of 5 to 9 on a 0 to 10 scale. randomized to one of three groups group 1- 0.5 mg of capsaicin intraarticular group 2- 1 mg of capsaicin intraarticular (CNTX-4975) group 3- placebo control group. primary endpoint was area under the curve (AUC) for the change from baseline through week 12 in daily WOMAC (Western Ontario and McMaster Universities Arthritis Scale) pain with walking scores. -- FIRST RED FLAG- you can normally report your results as outcome at the end of the study (EOS) -- the pain was this, gave this drug and this was the pain at the END OF THE STUDY or you can report it as area under the curve. NOW area under the curve (AUC) is a summary measure that integrates serial assessments of a patient's endpoint over the duration of the study- so pain was this and gave medication then at 6 weeks pain was this then 12 weeks pain was this and 24 weeks pain was this- some will argue that this format means AUC better reflects the clinical course of the disease. they will say well looking at it in a single point in time doesnt tell me anything about the rest of the time and they are correct but when you look at multiple time periods it becomes very risky that you will maybe skew the data and say well we are going to look at results at week 12 but then once you get the results you say - ‘’ well look at these shiny results with improved awesome amazing results at week 24, who cares about week 12 we are not going to report on week 24” enough of that rant- back to the study- music as I mention the primary outcome was AUC at 12 weeks and not your typical pain scales, the authors results were “In this study, capsaicin provided dose-dependent improvement in knee OA-associated pain. capsaicin 1.0 mg produced a significant decrease in OA knee pain through 24 weeks; capsaicin 0.5 mg significantly improved pain at 12 weeks, but the effect was not evident at 24 weeks.” this is exactly what I am talking about! Your primary outcome was 12 weeks but you read the results and they brag about the results at 24weeks. it smells like- drug money and you are correct! Centrexion Therapeutics was the sponsor of the study, controlled the study and my guess is they manipulated the numbers because when you go to clinical trials.gov they dont say they are going to use area under the curve they just say the difference in pain score. They dont say they are going to use least square mean they just do it. this trial is a scam I suspect - after all they were only looking for a 0.45 effect size-- you have a ten point scale and you power the study to find a 0.45 difference-- the cool thing and annoying thing about powering your study is you have to power it for a change that you think is clinically important, there is no rules on how big your study has to be it just has to be big enough to rule in or rule out the effect you are looking for. THEY THOUGHT A 0.45 difference was a good outcome! and this is clear because when you look at the benefit there is a p value of 0.00001 which makes you think WOW this is so great till you realize the individuals that got placebo had a 2 point improvement in their pain scales and those that got the capsaicin injection had roughly a 2.7 improvement in their pain scale. for me this is a no go and I can promise you drug reps will be in your office pushing this, you will hear about it at conferences or maybe even your colleagues will say this is the hot new thing, and I will say it is hot, so hot I actually dropped this article in the trash right next to the 0.5mg and 1mg capasaicn injection.
Hi everybody, today we're interviewing Anna Moshkovich, who is an MS2 at Rush Medical College! Today Anna will go into the interview day at Rush, student life, and other unique aspects about the school. Enjoy! Anna's email: anna_moshkovich@rush.edu Music: Tropical Traveller by Del. https://soundcloud.com/del-sound Disclaimer: The insights discussed in this podcast only hold true to this one student and do not represent the entire medical school, its constituents, or anyone else affiliated with the school. This student is not an official representative of the school and the opinions shared should not be seen as facts that the school has confirmed.
In the 4th episode of the “The Best and Worst” mini series, Alex Harrelson, MS2, and Shadi Awad, MS2, sit down with endocrine and general surgeon, Dr. John Porterfield, to discuss his career and what life is truly like as an endocrine and general surgeon. Tune in to also hear Dr. Porterfield discuss the importance[...]
Hi everybody, today we're interviewing Nathan Graham, who is an MS2 at the University of Michigan Medical School! Today Nathan will go into the interview day at Michigan, student life, and other unique aspects about the school. Enjoy! Music: Tropical Traveller by Del. https://soundcloud.com/del-sound Disclaimer: The insights discussed in this podcast only hold true to this one student and do not represent the entire medical school, its constituents, or anyone else affiliated with the school. This student is not an official representative of the school and the opinions shared should not be seen as facts that the school has confirmed.
The first PUBLIC LaidBlack discusses the vast disparities seen in COVID-19, worsened in smaller indigenous communities like the Navajo Nation. The discussion will be led by a panel consisting of students and faculty who'll be speaking on these disparities. Link to the presentation from live Zoom session: https://prezi.com/nlwkbg5ixcvu Panelists: Farrah-Amoy Fullerton, MS4- Administrative Leader of Student-Led Anti-Racism Movement at UABSOM Dr. Samantha Hill, President, UAB Minority Health and Health Research Center Young Professionals Board Neda Ilieva, MS2, MD-Ph.D. Candidate interested in the Pathology of Neurodegeneration Edgar Soto, M3, MSPH Candidate interested in Surgical Health Disparities in Underserved Communities
Hi everyone! Our names are Anvesh and Himakar, we're rising MS2's at UC Irvine SOM. We're creating this podcast to make applying to Medical School easier by giving pre-meds an in-depth look at various schools across the country. We want to give you all advice about applying in general as well, and allow you all to ask us questions which will help you navigate the premed path a little easier. Hopefully the information from the podcast episodes can help you make your decisions eventually about where you'd like to attend Medical School. So, please tune in every week to hear about a new Medical School, and please reach out to us at oncallmedstudent@gmail.com if you have any comments, questions, or suggestions! Song credits go to: https://soundcloud.com/kontekstmusic/buddha
In our last episode of the season, we look at 5 recent publications in the field of toxicology.Steuer, A. et al. Identification of new urinary gamma-hydroxybutyric acid markers applying untargeted metabolomics analysis following placebo-controlled administration to humans. (2019) Drug Testing and Analysis. 11 (6):813-823Souza, R. et al. Validation of an analytical method for the determination of the main ayahuasca active compounds and application to real ayahuasca samples from Brazil. (2019) Journal of Chromatography B. 1124: 197-203 Snamina, M. et al. Postmortem analysis of human bone marrow aspirate - Quantitative determination of SSRI and SNRI drugs. (2019) Talanta. 204:607-612Fabresse, N. et al. Development of a sensitive untargeted liquid chromatography-high resolution mass spectrometry screening devoted to hair analysis through a shared MS2 spectra database: A step toward early detection of new psychoactive substances. (2019) Drug Testing and Analysis. 11 (5):697-708Sitasuwan, P. et al. Comparison of purified beta-glucuronidases in patient urine samples indicates a lack of correlation between enzyme activity and drugs of abuse metabolite hydrolysis efficiencies leading to potential false negatives.(2019) Journal of Analytical Toxicology. 43 (3):221-227Contact us at thetoxpod@sa.gov.auThe Toxpod is a production of Forensic Science SA and the South Australian Attorney General's Department. The opinions expressed by the hosts are their own and do not necessarily reflect the views of their employer.
Peter promised Jesus that "Even if I have to die with You, I will not deny You!" But before the night was over, Peter gave in to the spirit of fear and denied even knowing Jesus three times. After Jesus rose from the dead, the Holy Spirit helped Peter to overcome fear and boldly proclaim the Good News of Jesus to thousands of people. (Matthew 26:26-75) MS2 #jesuschrist, #christianpodcastsforkids, #kids, #storiesforkids, #biblestoriesforkids, #bedtimestoriesforkids, #christiankids, #familydevotions, #drivetimedevotions, #carridestories, #biblelessonsforkids, #fishbytesforkids, #fishbytes4kids, #fishbites4kids, #fishbitesforkids, #ronandcarriewebb, #roncarriewebb
Peter promised Jesus that "Even if I have to die with You, I will not deny You!" But before the night was over, Peter gave in to the spirit of fear and denied even knowing Jesus three times. After Jesus rose from the dead, the Holy Spirit helped Peter to overcome fear and boldly proclaim the Good News of Jesus to thousands of people. MS2
DNA microscopy法という分子や細胞の位置を、分子間の近接情報のみから再構成することができる新しい方法論について、原著論文とその周辺技術を中心に詳しく話しました。Show notes DNA Microscopy: Optics-free Spatio-genetic Imaging by a Stand-Alone Chemical Reaction…bioRixv (Open Acess) 論文のPDFが入手できます。 DNA Microscopy論文のFigure 1…PodcastではほぼFigure1の説明に終始しているので、これを見ながら…だと理解の助けになるのかもしれない… DNA Microscopy: Optics-free Spatio-genetic Imaging by a Stand-Alone Chemical Reaction…Cell Press. Joshua Weinsteinのセミナー動画 (YouTube)…1st author Joshua Weinsteinが論文には書かれていない背景なども含めてDNA microscopyについてBroad研で発表した動画。 dnamic (GitHub)…DNA microscopyのデータ解析に使われたpythonのコード In-gel PCR…Four-arm PEG acrylateとHS-PEG-SHというポリエチレングリコール (PEG)をPCR反応液に追加することにより、高温下でも分子の拡散を抑えることができる。この液体の中で、Overlap extension PCRが起き、それぞれのUMIは新しいタグを持ちながら増幅され、近接する2つのUMIを持つ分子同士はUEIを受け取りつつ連結される。 Overlapping extension PCR Virtual microfluidics for digital quantification and single-cell sequencing. Nature Methods 2016…In-gel PCRの元論文。 In situ cDNA synthesis…固定した細胞に対しても逆転写酵素とプライマーなどを用いてcDNA合成を行うことができる。これを利用することで、細胞内でRNA分子の配列をその場でシーケンシングすることがIn situ RNA sequencing (FISSEQ法)で可能になった。 Fluorescent In Situ Sequencing (FISSEQ) Illumina sequencing…一塩基ごとに蛍光標識されたdyeを用いた伸長反応により大量のDNA配列を決定する。こちらのYoutubeの動画が原理を知るにはわかりやすい。 A Theory of Network Localization A remark on global positioning from local distances… Locally rigid embeddingのオリジナル論文。 ブラウン運動…何故、あるUMIを持つDNAが溶液中を移動して、異なるUMIを持つDNAと出会い、Overlap extension PCRを介して、新たなUEIを形成することができるのか。DNA microsocpyで明らかにしようとしている空間サイズでは、PCRに用いられるような高温にしてしまうと、一瞬でDNA群は均一に混じり合ってしまうことが予想されるが、粘度が高いゲル中でPCR反応を行うことにより、DNA分子の拡散を抑えることができる。これにより、UMI diffusion cloudsが形成される。 距離空間 (Wikipedia) 正規分布 (Wikipedia) Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Lieberman-Aiden et al. Science, 2009…Hi-C法のオリジナル論文。この論文を起点として、核内における染色体高次構造、クロマチン構造解析が爆発的に進むようになった。この方法も光学系ではなく、シーケンシングによってクロマチン構造を明らかにしようというコンセプトからなる。DNA配列同士の”Contact Probability”を中心にしている。 光学顕微鏡の解像度の限界:回折限界…蛍光顕微鏡を用いる際の回折限界は、波長の大きさとレンズの開口数によって計算することができる。 超解像顕微鏡法…2014年に超解像顕微鏡法がノーベル賞を受賞したときに書かれた阪大永井先生の総説。超解像顕微鏡法とは回折限界以下で行うことができる蛍光イメージングのことを指す。PALM, STORM, STED, SIMなど様々な方法が現在用いられている。 ハウスキーピング遺伝子…どの細胞においても定常的に多量発現している遺伝子のこと。GAPDH（glyceraldehyde-3-phosphate dehydrogenase)、β-アクチンなどが含まれる。DNA microscopy法でもbeaconとしてACTBやGAPDHが用いられた。 V(D)J recombination (Wikipedia)…B細胞やT細胞ではランダムな遺伝子群の組み換え反応 (recombination)により、ウィルスやがん細胞など多様な抗原に作用する抗体が作り出される。 smFISH…蛍光標識した蛍光プローブを用いることで一分子のRNAの位置を調べることができる。 MS2 tagging (Wikipedia)…MS2 RNAとそれに結合するMCPタンパク質を組み合わせることで生細胞で特定のRNAを可視化することができる。 CLARITY (Wikipedia)…厚みのある組織の透明化技術の一つ。 DNA Microscopyのsohによるメモ Editorial notes Cell誌のTheoryセクションということもあり、日本ではほとんど報道もなく紹介記事も見当たらない中、このDNA microscopyという画期的なコンセプトが伝わればいいと思いますが果たして…(soh) カンゼンニリカイシタ (coela) トリッキーな内容と論文の文体から、とてもスマートに感じるDNA microscopyであるが、内容を理解していくにつれて、案外膨大な試行の先にたどり着いた泥臭い方法論なのではないかと思うようになった。枯れたテクノロジーをできるだけ使いたい保守派研究者としては、DNA microscopyに対して思うことはたくさんある。しかし、そのモヤモヤは一度横に置き、自分の研究にどのように応用できるか、そしてこれからのどのように発展するか、その行き先を見つめていきたい (tadasu)
This week the guys welcome Abdalla's long time friend Jessica onto the show. She spoke on how & why she founded the "Make It Gorjess Prom Dress Drive" for young women who attends their old junior high school MS2. Where she drew inspiration from to create the prom dress drive & making it an annual event. They also discuss senator Mitchell McConnell saying reparations for African Americans isn't a good idea for the country, immigrant children at the border being subjected to under adequate conditions. Such as lack of toothpaste, soap, sleeping on cement floors & given aluminum blankets. Jessica also gives her thoughts on women asking men they are dating for money and more. Hear it all on this week's new episode. Created & curated by: Nico/Abdalla Our guest: Jessica IG: @tresrare_nico/@mrhazel_ Our guest IG: @jessijay92 Podcast IG: @brothersspodcast Twitter: @VeryrareNico/@MrHazel_ Email: brothersspodcast@gmail.com Enjoy Rate & Subscribe !
Bring back Bedside Rounds with tips from a master clinician educator, Jeff Wiese MD MACP (Tulane). How to accomplish teaching in the hospital is not on the curriculum for most folks in medical school or residency. This can feel especially daunting as you move from resident to attending. We address strategies to assess, monitor, teach, and coach the medical learners under your leadership with teaching wizard and coach extraordinaire, Dr. Jeff Wiese, recipient of over 50 teaching awards! ACP members can claim CME-MOC credit at https://acponline.org/curbsiders (CME goes live at 0900 ET on the release date). Full show notes available at http://thecurbsiders.com/episode-list. Join our mailing list and receive a PDF copy of our show notes every Monday. Rate us on iTunes, recommend a guest or topic and give feedback at thecurbsiders@gmail.com. Credits Written and Produced by: Matthew Watto MD FACP and Beth Garbitelli MS1 (almost MS2!) CME questions by: Matthew Watto MD FACP Hosts: Stuart Brigham MD, Paul Williams MD FACP, Matthew Watto MD FACP Images and infographics: Beth Garbitelli MS1 Edited by: Matthew Watto MD FACP, Emi Okamoto MD Guest: Jeff Wiese MD MACP Time Stamps 00:00 Intro, disclaimer, guest bio 03:28 Guest one-liner, love of Aaron Sorkin, book recommendations 10:52 Setting goals and expectations on day one 23:52 Preparing the resident for autonomy and assessing their place on the scale of supervision to autonomy 28:18 How to prepare for rounds as an attending to set yourself up for efficiency and success; The cardinal rule for being an attending 33:50 How long does it take determine a resident’s readiness for autonomy; Give your colleagues an “educational signout” 38:31 How to handle a request for card flipping; Prodiving a rationale for bedside rounds 43:54 The three Ds of Rounding; Should there be a fourth D 47:28 The choreography of bedside rounds; Privacy concerns; More on the rationale 63:00 How to handle unanswered questions in front of the patient 67:19 Resident as a “proud parent” on rounds 68:30 Rounding without the team (the afternoon) 73:18 Hand sanitizer (the Purell) 79:45 Advice to new PGY2s 81:35 When and how to incorporate teaching on high value care (specifically labs) 83:22 What’s the role of medical student on the wards team 85:18 Take home points 89:04 Plug: Teaching in the Hospital Deux 90:12 Outro
Dr. Nakul Singh joins the show to share his experience preparing for the ophthalmology match. He provides practical advice based on each of the various sections of the ERAS application.
Meet Steven and learn about his plan to help medical students match into competitive residencies! Also included are statistics from the NRMP 2018 Match.
In this episode, Joshua E. Novy, and Joseph Twanmoh, MD MBA FAAEM, discuss bottlenecks in the emergency department. Mr. Novy is a at University of Miami Miller School of Medicine and Vice President of the '18-'19 RSA Medical Student Council. Dr. Twanmoh is the Senior Vice President for MS2 and Course Director for AAEM's ED Management Solutions course.
Presented by Joshua E. Novy, student at University of Miami Miller School of Medicine and Vice President of the RSA Medical Student Council, and Joseph Twanmoh, MD MBA FAAEM, Senior Vice President for MS2 and Course Director for AAEMs ED Management Solutions course. Intro music by Akashic Records, Key to Success - Discover the Possibility from the album Corporate Presentation - Key to Success, powered by JAMENDO.
Allison is back! It's double Dr. Gray for today's episode about medical school. We talked about our experiences during the first two years of medical school. Links and Other Resources Full Episode Blog Post Check out my Premed Playbook series of books (available on Amazon), with installments on the personal statement, the medical school interview, and the MCAT. Related episode: Welcome to Your Third Year of Medical School. Related episode: Top 7 Things You Should Know as a Medical Student. Need MCAT Prep? Save on tutoring, classes, and full-length practice tests by using promo code “MSHQ” at Next Step Test Prep!
Joseph Twanmoh, MD MBA FAAEM, Co-Chair of the AAEM Operations Management Committee and Senior Vice President of MS2, a health care consulting firm and Ferdinando Mirarchi, DO FAAEM, an emergency physician at UPMC Hamot in Eire, PA, discuss solutions to address emergency department overcrowding. Intro music by SaReGaMa, 'Sky is the Limit,' from the album 'Sky is the Limit,' powered by JAMENDO.
Carl kennedy & MYNC project feat roachford - ride the storm Michael gray - the weekend Joey negro - must be the music Freemasons feat amanda wilson - watchin' Blaze feat barbara tucker - most precious love Stonebridge feat therese - put ' Em high Sessomatto feat Carolyn Harding - you're gonna love me Milk & sugar presebts MS2 - stay around Shakedown - at night Soul central feat kathy brown - strings of life Solu music feat kimblee - fade chris B feat janine small - 24 hours
Joseph Twanmoh, MD MBA FAAEM, Co-Chair of the AAEM Operations Management Committee and Senior Vice President of MS2, a health care consulting firm and Tom Scaletta, MD FAAEM, President, Smart-ER; ED Chair at Edward Hospital (Naperville, IL); and Past President of AAEM discuss solutions to address emergency department over-utilizers. Intro music by SaReGaMa, 'Sky is the Limit,' from the album 'Sky is the Limit,' powered by JAMENDO.
PAX Australia only finished a handful of hours ago, so it’s perfect timing for some semi-informed gaming discussion. We welcome as a guest Brendan from the Hungry Gamers podcast Talking Points – What we’ve been playing – PS VR thoughts – Nintendo Switch – Mass Effect Andromeda and MS2 and 3 now backwards compatible on […]
Joseph Guarisco, MD FAAEM, ED Chair at Ochsner Hospital (New Orleans, LA) and Co-Chair of the AAEM Operations Management Committee, interviews Joseph Twanmoh, MD MBA FAAEM, Co-Chair of the AAEM Operations Management Committee and Senior Vice President of MS2, a health care consulting firm. In part two of this episode, Drs. Guarisco and Twanmoh conclude their discussion of common myths in ED operations surrounding crowding and ED throughput and dive into best practices. Intro music by SaReGaMa, 'Sky is the Limit,' from the album 'Sky is the Limit,' powered by JAMENDO.
Joseph Guarisco, MD FAAEM, ED Chair at Ochsner Hospital (New Orleans, LA) and Co-Chair of the AAEM Operations Management Committee, interviews Joseph Twanmoh, MD MBA FAAEM, Co-Chair of the AAEM Operations Management Committee and Senior Vice President of MS2, a health care consulting firm. In part one of this episode, Drs. Guarisco and Twanmoh discuss common myths in ED operations surrounding crowding and ED throughput. Intro music by SaReGaMa, 'Sky is the Limit,' from the album 'Sky is the Limit,' powered by JAMENDO.
In this episode, we discuss the Summer Research Program (SRP) through the eyes of two MS2's, Katie Sullivan and Kevin Wymer. If you have questions for us, please send them to pritzkerquestions@gmail.com. Or, call (773) 336-2POD and leave us a message. Click here to get the full transcript for this episode.
It is going to be a great time talking to Marcy from MS2 Enterprises and the creator of the MS2 premium chow. We will be disscussing what it takes to properly feed your feeder insects in order for them to pass on optimal nutrition to our pets. You are what you eat right? That goes for our special pets too. MS2 is also a proud sponsor of Gecko Nation radio. Don't miss this valuable episode! We are now on Itunes! Please also check out the MS2 website at http://ms2ent.weebly.com Please also check out: www.davidsfinegeckos.com (Under construction) Facebook pages: www.facebook.com/davidsfinegeckos www.facebook.com/GeckoNationRadio https://www.facebook.com/pages/Flexwatt-Reptile-Heat-Tape/609249295755580 Gecko Nation Radio airs every Sunday at 8:00 P.M. Eastern Time on Blog Talk Radio at www.blogtalkradio.com/GeckoNationRadio and on Itunes
downloaded at mediafire: http://www.mediafire.com/?56q27hc6hgcs4zc 1) I Was Here (J-C Club Mix) BEYONCE 2) Domino (eSQUIRE vs OFFBeat Mix) JESSIE J 3) Trouble (Wideboys Club Mix) LEONA LEWIS 4) Summer Dreaming (Julia Luna Remix) KELLY ROWLAND 5) Call Your Girlfriend (Kaskade Club Mix) ROBYN 6) Alive (Extended Mix) ANNA GRACE 7) One Last Time (John Dahlback Remix) AGNES 8) Take Over Control (Bryan Reyes+Dale Jennings Private Mix) AFROJACK Ft. EVA SIMONS 9) Get Up (A Cowboys Anthem) KELLY CLARKSON 10) I Heart You (Peter Rauhofer Club Mix) TONI BRAXTON 11) Triumphant (Get 'Em) (Danny Verde Club Mix) MARIAH 12) Everything That I Got (Twisted Dee + Joe Magic Club Mix) KRISTINE W 13) Beautiful Nite (John W Remix) DOUBLE FACE BRAZIL ft. LORD BRUH 14) Lay Your Hands On Me (Tony Moran + Warren Rigg Club Mix) NICKI RICHARDS 15) Never Close Our Eyes (Mig + Rizzo Club Mix) ADAM LAMBERT 16) Blow Me (One Last Kiss) (Cosmic Dawn Remix) PINK 17) We Are Young (Bruno Ramos Rework) FUN ft JANELLE MONAE 18) Glad You Came (Alex Gaudino + Jason Rooney Club Mix) THE WANTED 19) Feel So Close (Extended Mix) CALVIN HARRIS 20) Stay Around (Spencer & Hill RMX) MILK + SUGAR pres.Ms2
© 2020-2025 Ivy Podcast Discovery LLC
